Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 85Recurrence 9Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 3Plasmacytoma 2Lymphoma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1POEMS Syndrome 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Genetic Diseases, Inborn 1Chromosome 17 deletion 1Alzheimer Disease 1

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
POEMS Syndrome × ixazomib × Plasma cell × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡